Table 3: **p15**

MAb ID	Location	WEAU	Sequence	Neutralizing	Immunogen	Species(Isotype)
136 EC6	p15(408-417 HXB2)	p15(31-40)	PRKKGCWKCG	N	rec p24-15	murine(IgG$_{2a,\kappa}$)

Donor: Bruce Chesebro and Kathy Wehrly, Rocky Mountain Laboratories, Hamilton, Montana
References: [Hinkula et al.(1990)]
NOTES:
- EC6: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 [Hinkula et al.(1990)]

MAb ID	Location	WEAU	Sequence	Neutralizing	Immunogen	Species(Isotype)
137 M12	p15(408-417 HXB2)	p15(31-40)	PRKKGCWKCG	N	rec p24-15	murine(IgG$_{1,\kappa}$)

Donor: Bruce Chesebro and Kathy Wehrly, Rocky Mountain Laboratories, Hamilton, Montana
References: [Hinkula et al.(1990)]
NOTES:
- M12: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 [Hinkula et al.(1990)]

MAb ID	Location	WEAU	Sequence	Neutralizing	Immunogen	Species(Isotype)
138 polyclonal	p55	p55		N	HIV-1 Pr-55gag VLP with anchored gp120 or V3+CD4 linear domains	Macaca mulatta

Donor: Bruce Chesebro and Kathy Wehrly, Rocky Mountain Laboratories, Hamilton, Montana
References: [Wagner et al.(1998)]
NOTES:
- A VLP is a non-infectious virus-like particle self-assembled from HIV Pr-55 gag – macaques were immunized with VLPs bound to either gp120 or V3+CD4 linear domains – gag and env CTL specific CTL were stimulated in each case, and Ab response to gag and gp120 and was elicited, but the gp120 CTL neutralizing response occurred only with whole gp120, not V3+CD4 – despite the CTL and Ab response, immunized macaques were infected by intravenous challenge with SHIV chimeric challenge stock [Wagner et al.(1998)]